A
Abivax
Stimulation of the immune system for the complete elimination of viral diseases using its unique antiviral platform technologies
About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapies that modulate the natural immune system machinery. The company leverages its immune-enhancing and antiviral platforms to create drug candidates aimed at treating chronic inflammatory diseases, viral diseases, and cancer. Abivax's lead clinical candidate, ABX464, is an oral, first-in-class small molecule that has shown significant anti-inflammatory effects in patients with moderate to severe ulcerative colitis (UC) during Phase 2a and Phase 2b clinical trials. The company also reported promising results in rheumatoid arthritis (RA) from Phase 2a clinical trials and preclinical studies in collagen-induced arthritis animal models.
Abivax primarily serves patients suffering from chronic inflammatory and viral diseases, as well as cancer. Operating in the biopharmaceutical market, the company follows a business model centered on the development and commercialization of innovative drug candidates. Revenue generation is expected to come from the successful commercialization of its lead candidates, partnerships, and potential licensing agreements.
Listed on the Paris stock exchange since June 26, 2015, Abivax continues to attract investor interest due to its promising clinical data and potential market impact.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2013
- Headquarters
- Paris, France
- Listing
- IPO 2015
- Employees
- 122
- Open positions
- 12
- Dealroom signal
- 92.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Infections and Infectious Diseases, Gastroenterology, Inflammatory Diseases, Chronic Disease, Spinout, Post IPO $1B
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 3 companies, latest Dec 2013
- Capital deployed
- —
- Preferred round
- MERGER
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Jul 2026 | $920M | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | Jun 2026 | $600M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Abivax is 23K monthly website visits, down 11.5% over the last three months. Abivax's team grew 40.2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Bpifrance
Series B and later14 investors entered at this stage
Kreos Capital
Deep Track Capital
Sofinnova Partners
TCGX- VPVenrock Healthcare Capital Partners
Boxer Capital
Commodore Capital
Deerfield
Great Point Partners
Invus
Samsara BioCapital
Claret Capital Partners
Heights Capital Management
Jefferies Group
Other known investors6 additional known investors
French National Centre for Scientific Research - CNRS
INSERM
Institut Curie
Paris-Saclay University
Andera Partners
Truffle Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Abivax on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Abivax’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.